Independent Testing to Accelerate the Development of Lateral Flow Assays for Influenza A, Influenza B and SARS-COV-2
The ITAP enabled rapid feedback to federal agencies and manufacturers on the analytical and clinical performance of over-the-counter LFAs for SARS-CoV-2 and influenza, ultimately contributing to success in regulatory authorization or clearance.
Authors
- Greg Martin
- Mark Griffiths (ORCID: https://orcid.org/0000-0001-8612-1783)
- Julia Tisheh
- Heather B. Bowers (ORCID: https://orcid.org/0000-0001-8758-8633)
- Leda Bassit (ORCID: https://orcid.org/0000-0001-9894-5587)
- Pamela N. Miller
- Gregory L. Damhorst (ORCID: https://orcid.org/0000-0002-2237-1713)
- Eric C. H. Lai (ORCID: https://orcid.org/0000-0001-6551-9231)
- Anuradha Rao
- Kathy Bifulco
- Emily B. Kennedy
- Julie A. Sullivan
- Wilbur A. Lam
- Kaleb B McLendon
- Seegar Swanson
- Jennifer K Frediani
- Annette Esper
- Raymond F Schinazi
- Chelsea Rock
- Laura Johnson
- Courtney Sabino
Institutions
- Emory University (US)
- The Wallace H. Coulter Department of Biomedical Engineering (US)
- Grady Health System (US)
- Pulmonary and Allergy Associates (US)
- Children's Healthcare of Atlanta (US)
- aTyr Pharma (United States) (US)
- Think A Move (United States) (US)
- Excelsior College (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1093/cid/ciaf660
- Primary Topic
- SARS-CoV-2 detection and testing
- Type
- article
- Field-Weighted Citation Impact
- 0.00